A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

January 3, 2025

Study Completion Date

January 3, 2025

Conditions
Hyperkalaemia
Interventions
DRUG

sodium zirconium cyclosilicate (SZC)

sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.

Trial Locations (10)

10676

Research Site, Athens

11527

Research Site, Athens

12462

Research Site, Athens

15123

Research Site, Athens

26504

Research Site, Pátrai

41110

Research Site, Larissa

54636

Research Site, Thessaloniki

57010

Research Site, Thessaloniki

68100

Research Site, Alexandroupoli

71500

Research Site, Heraklion

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY